Please use this identifier to cite or link to this item:
Title: Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial.
Authors: Papadaki, Angeliki
Martínez-González, Miguel Ángel
Alonso-Gómez, Angel
Rekondo, Javier
Salas-Salvadó, Jordi
Corella, Dolores
Ros, Emilio
Fitó, Montse
Estruch, Ramon
Lapetra, José
García-Rodriguez, Antonio
Fiol, Miquel
Serra-Majem, Lluís
Pintó, Xavier
Ruiz-Canela, Miguel
Bulló, Monica
Serra-Mir, Mercè
Sorlí, Jose V
Arós, Fernando
Keywords: Cardiovascular disease;Heart failure;Mediterranean diet;PREDIMED study
metadata.dc.subject.mesh: Aged
Cardiovascular Diseases
Diet, Mediterranean
Dietary Supplements
Heart Failure
Middle Aged
Olive Oil
Outcome and Process Assessment, Health Care
Risk Assessment
Statistics as Topic
Issue Date: 30-Jan-2017
Abstract: The aim of this study was to evaluate the effect of the Mediterranean diet (MedDiet) on the incidence of heart failure (HF), a pre-specified secondary outcome in the PREDIMED (PREvención con DIeta MEDiterránea) primary nutrition-intervention prevention trial. Participants at high risk of cardiovascular disease were randomly assigned to one of three diets: MedDiet supplemented with extra-virgin olive oil (EVOO), MedDiet supplemented with nuts, or a low-fat control diet. Incident HF was ascertained by a Committee for Adjudication of events blinded to group allocation. Among 7403 participants without prevalent HF followed for a median of 4.8 years, we observed 29 new HF cases in the MedDiet with EVOO group, 33 in the MedDiet with nuts group, and 32 in the control group. No significant association with HF incidence was found for the MedDiet with EVOO and MedDiet with nuts, compared with the control group [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.41-1.13, and HR 0.92; 95% CI 0.56-1.49, respectively]. In this sample of adults at high cardiovascular risk, the MedDiet did not result in lower HF incidence. However, this pre-specified secondary analysis may have been underpowered to provide valid conclusions. Further randomized controlled trials with HF as a primary outcome are needed to better assess the effect of the MedDiet on HF risk. ISRCTN35739639.
metadata.dc.identifier.doi: 10.1002/ejhf.750
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.